CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

  • Neurodegenerative Disorder
  • Alzheimer's Disease (AD)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • Aarhus
  • Albacete
  • Albany
  • Amadora
  • Amherst
  • Ankara
  • Atlanta
  • Auburn
  • Austin
  • Barcelona
  • Basel
  • Beachwood
  • Białystok
  • Bobigny
  • Bradenton
  • Brno-Bohunice
  • Bron
  • Budapest
  • Burgos
  • Caulfield
  • Charleston
  • Charlotte
  • Culiacán Rosales
  • Dallas
  • Danbury
  • Dayton
  • Decatur
  • Delray Beach
  • El Palmar
  • Elk Grove Village
  • England
  • Eskişehir
  • Esplugues de Llobregat
  • Fairfield
  • Flowood
  • Fort Worth
  • Fujisawa
  • Fulwood
  • Gdańsk
  • Genova
  • Gent
  • Greensboro
  • Greifswald Hansestadt
  • Gwangju
  • Hachioji
  • Headington
  • Heidelberg
  • Hialeah
  • Hiroshima
  • Hlavní město Praha
  • Hong Kong Island
  • Hradec Králové
  • Incheon
  • Indianapolis
  • İstanbul
  • Jacksonville
  • Joetsu
  • Kalamazoo
  • Kansas City
  • Kaunas
  • Kazan
  • Kodaira
  • Kurashiki
  • Kyiv
  • Kyoto
  • København
  • L'Hospitalet de Llobregat
  • Lamezia Terme
  • Linz
  • London
  • Long Beach
  • Los Alamitos
  • Los Angeles
  • Loures
  • Lugo
  • Lviv
  • Madrid
  • Matsumoto
  • Merritt Island
  • Miami
  • Milano
  • Monterrey
  • Montpellier
  • Morioka
  • Moscow
  • Moskva
  • Murray
  • Málaga
  • München
  • Münster
  • New Haven
  • New Territories
  • New York
  • Newport Beach
  • Norfolk
  • Norwalk
  • Nyíregyháza
  • Nürnberg
  • Obu
  • Ocala
  • Oklahoma City
  • Orlando
  • Ota City
  • Otake
  • Ottawa
  • Palo Alto
  • Pamplona
  • Paris
  • Patchogue
  • Perugia
  • Peterborough
  • Philadelphia
  • Phoenix
  • Plasencia
  • Poitiers
  • Port Orange
  • Portland
  • Poznań
  • Québec
  • Redlands
  • Rho
  • Richmond
  • Roma
  • Rostock
  • Sacramento
  • Saint Petersburg
  • Salamanca
  • Saltillo
  • Samsun
  • San Francisco
  • San José
  • Sankt-Peterburg
  • Sant Cugat del Vallès
  • Santa Monica
  • Santander
  • Sapporo
  • Saratov
  • Scarborough
  • Seoul
  • Setagaya City
  • Sherbrooke
  • Shinjuku City
  • Siemianowice Śląskie
  • Skåne län
  • Sofia
  • Springfield
  • Springfield Township
  • St. Louis
  • Stockholms län
  • Strasbourg
  • Szeged
  • Takamatsu
  • Tampa
  • Tampere
  • Tatabánya
  • Terrassa
  • The Villages
  • Toms River
  • Toronto
  • Torrance
  • Toulouse
  • Tsu
  • Tulsa
  • Turku
  • Ulm
  • Upravna enota Maribor
  • València
  • Vancouver
  • Victoria
  • Vilnius
  • Vác
  • Västra Götalands län
  • Warszawa
  • Wauwatosa
  • Wellington
  • West Palm Beach
  • West Perth
  • Westerstede
  • Willow Grove
  • Witten
  • Woodstock
  • Woodville South
  • Yonago
  • Zaragoza
  • Łódź
  • 横浜市
Trial Identifier:

NCT02670083 BN29552

      Show trial locations

      The source of the below information is public registry websites such as,,, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to and/or and/or

      The below information is taken directly from public registry websites such as,,, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (Q4W) for 100 weeks. The final efficacy and safety assessment will be performed 52 weeks after the last crenezumab dose. Participants will then have the option to enter the Open Label Extension (OLE) study if eligible. Participants who do not enter the OLE study will have additional follow-up visits at 16 and 52 weeks after the last dose, primarily for safety and also for limited efficacy assessments.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02670083,BN29552,2015-003034-27 Trial Identifier
      Crenezumab, Placebo Treatments
      Alzheimer's Disease Condition
      Official Title

      A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease.

      Eligibility Criteria

      All Gender
      ≥50 Years & ≤ 85 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Weight between 40 and 120 kilograms (Kg) inclusive
      • Availability of a person (referred to as the "caregiver") who in the investigator's judgment:
      • Has frequent and sufficient contact with the participant to be able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits (which require partner input for scale completion), signs the necessary consent form, and has sufficient cognitive capacity to accurately report upon the participant's behavior and cognitive and functional abilities
      • Fluency in the language of the tests used at the study site
      • Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted)
      • Evidence of the AD pathological process, by a positive amyloid assessment either on cerebrospinal fluid (CSF) amyloid beta 1-42 levels as measured on the Elecsys beta-amyloid(1-42) test system or amyloid PET scan by qualitative read by the core/central PET laboratory
      • Demonstrated abnormal memory function at screening (up to 4 weeks before screening begins) or screening (FCSRT cueing index =<0.67 AND free recall =<27)
      • Screening mini mental state examination (MMSE) score of greater than or equal to (>=) 22 points and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 or 1.0
      • Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment (MCI)
      • If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening
      • Participant must have completed at least 6 years of formal education after the age of 5 years
      Exclusion Criteria
      • Any evidence of a condition other than AD that may affect cognition such as other dementias, stroke, brain damage, autoimmune disorders (e.g. multiple sclerosis) or infections with neurological sequelae.
      • History of major psychiatric illness such as schizophrenia or major depression (if not considered in remission)
      • At risk of suicide in the opinion of the investigator
      • Any abnormal MRI findings, such as presence of cerebral vascular pathology, cortical stroke, etc or inability to tolerate MRI procedures or contraindication to MRI
      • Unstable or clinically significant cardiovascular (e.g., myocardial infarction), kidney or liver disease
      • Uncontrolled hypertension
      • Screening hemoglobin A1c (HbA1C) >8%
      • Poor peripheral venous access
      • History of cancer except:

      If considered to be cured or If not being actively treated with anti-cancer therapy or radiotherapy

      • Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now